NousCom Raises €42m For Novel Cancer Vaccines
Executive Summary
European biotech NousCom is making ready two multi-neoantigen containing vaccines that with a new round of VC funding should enter clinical studies in 2018, and that it hopes to combine with checkpoint inhibitors.
You may also be interested in...
NousCom CEO Outlines Cancer Vaccine Strategy
NousCom CEO and co-founder Alfredo Nicosia speaks to Scrip senior editor Lucie Ellis during BIO-Europe, a partnering meeting held in berlin Nov. 6-8, about the company's recent series B financing.
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?
Need a specific report? 1000+ reports available
Buy Reports